Weil is advising longtime client Sanofi in its asset swap transaction with Boehringer Ingelheim, the eighth largest consumer healthcare business in the world. The transaction will consist of an exchange of Sanofi’s animal health business, with an enterprise value of €11.4 billion, and Boehringer Ingelheim’s consumer healthcare business, with an enterprise value of €6.7 billion, and will include a gross cash payment from Boehringer Ingelheim to Sanofi of €4.7 billion. The transaction allows Sanofi to become the number one ranked player in global consumer healthcare. The transaction is expected to close in Q4 2016, subject to appropriate regulatory approvals.

The Weil team was led by Corporate Chairman Michael Aiello and Corporate partner Shayla Harlev. The deal team also included Senior Partner of Weil’s Paris office Claude Serra and Corporate partner Yannick Piette; Antitrust partner John Scribner; Tax partner Jared Rusman; Executive Compensation & Benefits head Paul Wessel and partner Joanne Etherton; Technology & IP Transactions head Michael Epstein and partner Jeffrey Osterman; Insurance partner Joseph Verdesca; Antitrust counsel Brianne Kucerik; Real Estate counsel Elliot Ganchrow; Environmental counsel Thomas Goslin; Corporate associates Maxwell Copelan, Mariel Cruz, Maryam Naghavi, Kevin Kitson, Amanda Border, Natalia Caruso, Sarah Damerville, Emily Willey and Adam Borenstein; Antitrust associates Christopher Abbott and Brittany Constance (not yet admitted); Tax associate Ryan Roberts; Executive Compensation & Benefits associate Jennifer Britz; and Technology & IP Transactions associates Cheri Bessellieu, Mary Lentowski, Eric Leventhal, Lauren Springer, Jennifer Yoon and Jasmine Rose (not yet admitted).